A Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group, Phase 3 Study to Evaluate the Effects of Macitentan on Exercise Capacity in Subjects With Eisenmenger Syndrome

Trial Profile

A Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group, Phase 3 Study to Evaluate the Effects of Macitentan on Exercise Capacity in Subjects With Eisenmenger Syndrome

Completed
Phase of Trial: Phase III

Latest Information Update: 30 Aug 2017

At a glance

  • Drugs Macitentan (Primary)
  • Indications Eisenmenger complex
  • Focus Registrational; Therapeutic Use
  • Acronyms MAESTRO
  • Sponsors Actelion Pharmaceuticals
  • Most Recent Events

    • 30 Aug 2017 Results of MAESTRO study (n=226) and its haemodynamic substudy (n=39) presented at the ESC Congress 2017: Annual Congress of the European Society of Cardiology
    • 23 Jan 2017 Results published in an Acetelion Pharmaceuticals media release.
    • 23 Jan 2017 Primary endpoint has not been met. (Change from baseline to Week 16 in exercise capacity, as measured by 6MWD), as per an Acetelion Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top